🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Champix

    Hospital Authority, Hong Kong

    Tobacco Use Disorder

    phase 3 small molecule completed

    1 trial

  2. Chemotherapy

    The First People's Hospital of Lianyungang

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  3. Chemotherapy

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 3 small molecule completed

    1 trial

  4. Chemotherapy

    International Peace Maternity and Child Health Hospital

    Non Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  5. Chemotherapy drug

    Chinese PLA General Hospital

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  6. Chickenpox Vaccines

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chickenpox Vaccines

    phase 3 mab completed

    1 trial

  7. Cholecalciferol (Vitamin D/Vigantol oil)

    United Therapeutics Europe Ltd

    Respiratory Tract Infections

    phase 3 other completed

    1 trial

  8. Cisplatin

    Children's Hospital of Fudan University

    Localized Osteosarcoma

    phase 3 small molecule completed

    1 trial

  9. Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule completed

    1 trial

  10. Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Squamous Cell Carcinoma of Head and Neck

    phase 3 small molecule active

    1 trial

  11. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets

    AstraZeneca AB

    Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  12. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Ningbo Cancer Hospital

    Advanced head and neck cancer

    phase 3 small molecule active

    1 trial

  13. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer (CM), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 2927088, BAY 2927088 Bayer (CM), Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer

    Bayer AG

    Advanced non-small cell lung cancer with HER2 (ERBB2) mutation

    phase 3 small molecule active

    1 trial

  14. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 3 small molecule active

    1 trial

  15. Clamp-Crushing technique

    The First People's Hospital of Lianyungang

    Hepatobiliary Disease

    phase 3 other completed

    1 trial

  16. Clesrovimab

    Merck KGaA, Darmstadt, Germany

    Respiratory Syncytial Virus Infection

    phase 3 mab completed

    1 trial

  17. Co-Trimoxazole 960Mg Dispersible Tablet

    United Therapeutics Europe Ltd

    Spontaneous Bacterial Peritonitis

    phase 3 small molecule active

    1 trial

  18. Combined use of TPO-RAs with low-dose anti-CD20 antibody

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  19. Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Promyelocytic Leukaemia

    phase 3 small molecule active

    1 trial

  20. Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, Conjunctival Provocation Test Olea europaea LETI 30 HEP/ml, Depigoid DUO Grass-Mix/Olea (1000 DPP/ml + 1000 DPP/ml), PLACEBO (Depigoid): the placebo is the solvent used in the investigational medicinal products’ (IMP) formulation. The resulting product is a suspension.

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.

    phase 3 small molecule active

    1 trial

  21. Continuous Gastrocnemius plane block with ropivacaine

    The First People's Hospital of Lianyungang

    Foot Ankle Injuries

    phase 3 small molecule active

    1 trial

  22. Control

    Hospital Authority, Hong Kong

    Hallucinations, Verbal Auditory

    phase 3 small molecule active

    1 trial

  23. Coronary Artery Bypass Graft with the use of CPB

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    the Efficacy and Safety of Off-pump CABG

    phase 3 other completed

    1 trial

  24. Coronary CTA

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Artery Disease

    phase 3 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources